UNSPSC 51181905: Menotropin

This classification denotes extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, follicle stimulating hormone and luteinizing hormone, and which are used to treat infertility, preparations that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Y9QQM372Q, and generally arise in the molecular formula C42H65N11O12S2, chemically known as 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide, but generally known as menotropins, and sometimes also called urofollitropin, and which bear US NIH Compound Identifier 62819.

UNSPSC 51181905 Menotropin is a Commodity code for a specific pharmaceutical product, but recent state and local procurement activity under this code shows minimal direct engagement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products that spans a broad family of drugs rather than menotropin specifically. Menotropin—a hormone product used in fertility treatment—does not appear as a named line item in the MMCAP solicitation materials; instead, the RFP seeks manufacturers willing to supply comprehensive pricing catalogs across multiple therapeutic categories through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC). The scope emphasizes compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), FDA requirements, and detailed product data submission including National Drug Codes, SKUs, and packaging configurations. Vendors must maintain relationships with at least two of the three authorized wholesalers, carry commercial general liability insurance of at least $5,000,000 per occurrence, and accept a 3 percent administrative fee on all contract purchases.

The RFP represents a multi-state purchasing vehicle with participation from Minnesota and Oregon and is open to manufacturers willing to meet MMCAP's pricing and compliance framework. Proposals were due March 26, 2026, with contract awards effective July 1, 2026, and a two-year term for new responders. The cooperative structure and emphasis on multi-therapeutic pharmaceutical catalogs signal that state and local health agencies and ancillary facilities are consolidating pharmaceutical procurement through pooled demand, but the available solicitation materials do not isolate menotropin as a distinct procurement driver or flag it as a priority item for MMCAP members.